Nodality, Inc. today announced a strategic collaboration with Pfizer Inc. for the use of Nodality's proprietary Single Cell Network Profiling (SCNP) technology as a tool for the development of Pfizer compounds.
The agreement establishes a multi-year, collaborative effort that will initially focus on providing biological bases for streamlining the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis, and drug profiling. The agreement also provides Pfizer the option to engage Nodality in companion diagnostics development. The terms of the agreement include an upfront payment, R&D funding, and success-based milestone payments.
0 comments
- Get Livefyre
- FAQ
Newest | Oldest
